Food Allergies

• Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
• Common Allergens
• It’s a Disease, Not a Diet: A documentary about life with food allergies
• Children With Food Allergies
• Living with Food Allergies: Preparing for College
• Omalizumab for the Treatment of Multiple Food Allergies
• Omalizumab Prescribing Information
• Peanut Oral Immunotherapy Prescribing Information
• Clinical Burden of Food Allergies: Insights from the FARE Patient Registry
• Mental Health Burden of Food Allergies: Insights from Patients and Their Caregivers from FARE Patient Registry
• Food Allergies: National Institute of Allergy and Infectious Diseases
• Food Allergy Information from the American College of Allergy, Asthma & Immunology
• Kids With Food Allergies
• FARE powered by Sifter Shopping Tool for Food Allergy Needs
• Managing food allergy: GA2LEN guideline 2022

Asthma

• Dupilumab Prescribing Information
• Tezepelumab Prescribing Information
• Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
• Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
• American Lung Association: Severe Asthma
• Mepolizumab Prescribing Information
• National Jewish Health Inhaler Instructional Videos

Chronic Spontaneous Urticaria (CSU)

• Dupilumab in Patients With Chronic Spontaneous Urticaria Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials
• Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
• The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
• The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
• Never Just Hives – Patient Resource
• Chronic spontaneous urticaria and chronic inducible urticaria
• Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review
• First-Generation vs Second-Generation H1 Antihistamines for Chronic Urticaria: Systematic Review and Network Meta-Analysis
• Treatment of Recalcitrant Chronic Urticaria With Nonsedating Antihistamines: Is There Evidence for Updosing?
• Efficacy and Safety of Up-dosed Second-generation Antihistamines in Uncontrolled Chronic Spontaneous Urticaria: A Review
• Fexofenadine Prescribing Information
• The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized clinical trials
• Management of Chronic Spontaneous Urticaria Made Practical: What Every Clinician Should Know
• Urticaria Voices: Real-World Experience of Patients Living with Chronic Spontaneous Urticaria
• Chronic Spontaneous Urticaria: A Review
• Update on the Treatment of Chronic Spontaneous Urticaria
• Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: Evolving toward personalized medicine
• Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
• Remibrutinib in Chronic Spontaneous Urticaria
• Patient education: Hives (urticaria) (Beyond the Basics)

Acute Coronary Syndrome

• Acute Myocardial Infarction Toolkit
• Heart Disease: Resources for Individuals and Patients

Atherothrombosis

• 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee

Cardiac Imaging

• 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain

Dyslipidemia

• Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
• PREVAIL: Obicetrapib in ASCVD
• Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
• Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
• Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
• An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
• ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
• ACC Statin Intolerance Tool
• Cholesterol Tools and Resources

Familial Chylomicronemia Syndrome (FCS)

• Recognition and management of persistent chylomicronemia
• NAFCS Score for FCS: Development and validation
• NAFCS Score Calculator for FCS
• Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
• Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
• Patient Tear Sheet: What You Need to Know-FCS
• Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
• Understanding FCS – for Patients
• About FCS

Familial Hypercholesterolemia (FH)

• Diagnostic Criteria for Familial Hypercholesterolemia

Heart Failure (HF)

• Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
• Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
• Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
• Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
• Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
• Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
• Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
• Heart Failure: Patient Education

Hypertension

• CDC Facts About Hypertension
• High Blood Pressure Information for Patients

Hypertriglyceridemia

• Target Populations for Novel Triglyceride-Lowering Therapies
• Triglycerides. MedlinePlus.
• Fish and Omega-3 Fatty Acids

Hypertrophic Cardiomyopathy (HCM)

• Provider Tools: AHA HCM Educational Resources
• Provider Tools: Genetic Testing and Counseling for HCM
• Talking With Patients About Hypertrophic Cardiomyopathy
• Mavacamten Prescribing Information
• Mavacamten REMS (Risk Evaluation and Mitigation Strategy)
• Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
• VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
• Risk Stratification in HCM
• Hypertrophic Cardiomyopathy Association (HCMA)
• Encouraging Shared Decision Making in HCM
• Patient Info: HCM Action Plan
• Patient Info: HCM Fact Sheets
• Patient Info: HCM Genetic Testing
• Patient Info: Hypertrophic Cardiomyopathy

Lipoprotein (a) [Lp(a)]

• Patient Resource: What is Lipoprotein(a)?
• Patient Resource: Treating High Lp(a)
• Assessing Risk: Infographic on Lp(a) Screening

Venous Thromboembolism (VTE)

• What is Venous Thromboembolism (VTE)?
• Wells’ Criteria for Pulmonary Embolism

Alopecia

• National Alopecia Areata Foundation: Patient Resources
• Treatment Options for Alopecia Areata in Children and Adolescents
• Ritlecitinib Prescribing Information
• Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
• Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial
• Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
• Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort

Atopic Dermatitis

• Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice?
• Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand
• New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis
• Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity
• Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema
• Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis
• Therapeutic education in atopic dermatitis
• Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
• Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase 3 Trial

Prurigo Nodularis

• Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
• Prurigo Nodularis Signs and Symptoms – AAD Patient Resource
• Prurigo Nodularis Facts, Symptoms, Testing and Treatment – JAMA Patient Resource
• JAAD Health-related Quality of Life and Economic Burden of Prurigo Nodularis
• Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials (PRIME and PRIME2)
• Psychiatric Comorbidity and the Impact of Socioeconomic Status in Prurigo Nodularis

Psoriasis

• Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
• Psoriatic Disease Information for Parents/Caregivers
• Treatments for Psoriatic Disease – For Patients
• Psoriasis Clinical Guideline from the American Academy of Dermatology
• National Psoriasis Foundation

Diabetes Mellitus

• Diabetes-Related Macular Edema
• CDC Managing Blood Sugar
• AFP Publications: Type 2 Diabetes
• The Links Between Sleep Duration, Obesity and Type 2 Diabetes Mellitus
• Obesity Management as a Primary Treatment Goal for Type 2 Diabetes: Time to Reframe the Conversation
• AACE Diabetes Resource Center
• Family Practice Management Toolbox: Diabetes
• Diabetes and You: All Medicines Matter!
• Advanced Insulin Management: Using Insulin-to-Carb Ratios and Correction Factors
• Living with Diabetes

Acromegaly

• Acromegaly Patient Information

Osteoporosis

• NIH Handout on Health: Osteoporosis – Patient Handout

Chronic Cough

• Cough hypersensitivity and chronic cough
• Healthcare utilization and costs in chronic cough
• Incidence and Prevalence of Cough in a Rural Health System: A 20-Year Study
• On Chronic Cough Diagnosis, Classification, and Treatment
• Understanding the Foundations of Chronic Cough
• American Lung Association: Chronic Cough Resources and Videos
• European Respiratory Society Guidelines on the Diagnosis and Treatment of Chronic Cough in Adults and Children

Pain Management

• CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022

Peyronie’s Disease

• A clinical pathway for the management of Peyronie’s disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association
• JAMA Patient Page: Peyronie’s Disease
• Peyronie’s Disease

Substance Use Disorders

• NIH/National Institute on Drug Abuse – Patient Information
• Sublocade Prescribing Information

Biosimilars

• Biosimilars – What IBD Patients Should Know
• Biosimilar Patient and Prescriber Outreach Materials
• Biosimilar Development, Review, and Approval
• Biosimilars Basics infographic for Patients
• What is a Biosimilar?
• Prescribing Biosimilar Products
• Biosimilar Development Process

Eosinophilic Esophagitis (EoE)

• ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis
• EoE Management Playbook
• Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
• Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
• Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial
• Dupilumab Improves Health-Related Quality of Life and a Range of Symptoms in Patients With Eosinophilic Esophagitis
• Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study
• Proton Pump Inhibitors for Inducing and Maintaining Remission in Eosinophilic Esophagitis: An Updated Systematic Review and Meta-Analysis
• Insights into the natural history and disease course of eosinophilic esophagitis
• Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis

Hepatitis C Virus (HCV)

• AGA Hepatitis C Virus FAQs
• AGA GI Patient Center: Hepatitis C (HCV)
• Direct-Acting Antivirals: Side Effects Management Handouts
• CDC Hepatitis C Resource Center
• U.S. Department of Veterans Affairs: Hepatitis C Resources for Healthcare Professionals and Patients

Hepatitis B Virus (HBV)

• CDC Patient Education Center: Hepatitis B Virus
• CDC Interpretation of Hepatitis B Serologic Test Results

Inflammatory Bowel Disease (IBD)

• AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
• ACG Clinical Guideline: Management of Crohn’s Disease in Adults
• ACG Clinical Guideline Update: Ulcerative Colitis in Adults
• ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease
• Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches
• Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis
• Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis
• Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease
• TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
• Advanced Therapies for Inflammatory Bowel Disease: Navigating Payor and Financial Challenges
• Reaching the therapeutic ceiling in IBD: Can Advanced Combination Treatment (ACT) offer a solution?
• AGA IBD Patient Resources
• Resources For Nurses & Advanced Practice Providers: Crohn’s and Colitis Foundation
• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Crohn’s and Colitis Foundation Resources for Patients

• Crohn’s & Colitis Foundation. Free educational brochures
• Treatment Approaches in IBD: Shared Decision-Making
• Ostomy Tips and Tricks
• Living with Crohn’s Disease
• Living with Ulcerative Colitis
• CCF IBD Medication Guide
• UIcerative Colitis 101
• Crohn’s 101

Crohn’s and Colitis Foundation Resources for Clinicians

• IBD Nurse & Advanced Practice Provider Best Practices Resource Library
• Appeal Letters

Lysosomal Acid Lipase Deficiency (LAL-D)

• Lysosomal Acid Lipase Deficiency (LALD) – Patient Information

Non-Alcoholic Fatty Liver Disease (NAFLD)

• NAFLD: Differential Diagnosis – Summary
• NIH Genetic and Rare Diseases Information Center: Lysosomal acid lipase deficiency

Primary Biliary Cholangitis (PBC)

• NIH Overview for Primary Biliary Cholangitis
• The PBCers Guide to Primary Biliary Cholangitis
• PBC Foundation Patient Education Resource
• American Liver Foundation PBC Fact Sheet
• 2021 AASLD Practice Guidance Update for PBC

• Primary Biliary Cholangitis: A Pocket Guide

Biosimilars

• Biosimilar and Interchangeable Biologics: More Treatment Choices
• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
• Biosimilar Product Information

Bladder Cancer

• Immunotherapy for Bladder Cancer – American Cancer Society
• Bladder Cancer – Nation Cancer Institute – For Patients
• Bladder Cancer – Nation Cancer Institute – For Providers

Breast Cancer

• National Cancer Institute: Breast (Patient Version)
• National Cancer Institute: Breast (Health Professional Version)

Colorectal Cancer (CRC)

• NCCN Guidelines for Colon Cancer
• NCCN Guidelines for Rectal Cancer
• Colorectal Cancer Alliance: What are NTRK fusions?
• National Cancer Institute: Colorectal Cancer [patient version]
• National Cancer Institute: Colorectal Cancer [health professional version]
• National Cancer Institute: Drugs Approved for Colon and Rectal Cancer

General Hematology/Oncology

• Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
• NCCN Clinical Practice Guidelines in Oncology
• NCCN Guidelines for Patients
• CDC Recommended Screening Tests for Cancer
• American Cancer Society Guidelines for the Early Detection of Cancer

Hematologic Malignancies

• National Cancer Institute: Leukemia (Patient Version)
• National Cancer Institute: Leukemia (Health Professional Version)
• NCCN CLL Guidelines for Patients
• Leukemia & Lymphoma Society Patient Information Booklets
• Multiple Myeloma Research Foundation Patient Resources

Hematologic Malignancies and Disorders: Alpha Thalassemia

• Alpha-Thalassemia
• What is Thalassemia?

Hematologic Malignancies and Disorders: B-cell Lymphomas

• NCCN Guidelines for Patients: Mantle Cell Lymphoma
• NCCN Guidelines for Patients: Follicular Lymphoma
• NCCN Guidelines for Patients: DLBCL
• Leukemia & Lymphoma Society Patient Information Booklets

Hematologic Malignancies and Disorders: Chronic Lymphocytic Leukemia (CLL)

• CLL Guide: Information for Patients and Caregivers
• NCCN Guidelines: Chronic Lymphocytic Leukemia for Patients

Hematologic Malignancies and Disorders: Multiple Myeloma

• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Patient Version)
• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Health Professional Version)
• Treatment for Multiple Myeloma – for Health Professionals
• Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies and Disorders: Myelodysplastic Syndromes (MDS)

• About Myelodysplastic Syndromes (MDS)
• Myelodysplastic Syndromes
• Treating MDS Toolkit
• What is MDS? iPad App

Hemophilia

• World Federation of Hemophilia Guidelines for the Management of Hemophilia
• National Hemophilia Foundation Recommendations for Genotyping for Persons with Hemophilia
• Impact of novel hemophilia therapies around the world
• Centers for Disease Control and Prevention: Hemophilia Homepage
• National Hemophilia Foundation: Hemophilia A
• World Federation of Hemophilia: Guidelines for the Management of Hemophilia, 3rd Edition

Hepatocellular Carcinoma

• National Cancer Institute: Liver and Bile Duct Cancers (Patient Version)
• National Cancer Institute: Liver and Bile Duct Cancers (Health Professional Version)

Kidney Cancer

• Kidney Cancer – American Cancer Society
• Kidney Cancer – NIH – Patient Resources

Lung Cancer

• American Cancer Society Lung Cancer – Patient Information
• American Cancer Society Questions to Ask About Lung Cancer
• National Cancer Institute: Lung Cancer (Patient Version)
• National Cancer Institute: Lung Cancer (Health Professional Version)

Melanoma

• Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions
• Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
• Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
• Subcutaneous versus intravenous nivolumab
• Subcutaneous versus intravenous pembrolizumab
• First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
• Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
• Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
• Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial
• Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
• American Cancer Society: Immunotherapy for Melanoma Skin Cancer
• Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
• Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
• NCI: Oncolytic Virus Enables the Immune System to Attack Tumors Subscribe
• NCCN Guidelines for Patients: Melanoma
• NCCN Clinical Practice Guidelines in Oncology – Cutaneous Melanoma
• Melanoma Treatment – for health professionals
• Melanoma Risk Assessment Tool

Ovarian Cancer

• SGO Gynecologic Cancer Resources For Patients And Their Families
• ACOG Ovarian Cancer FAQs
• Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer
• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Patient Version)
• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Health Professional Version)

Uveal Melanoma

• Intraocular (Uveal) Melanoma Treatment (PDQ®): Patient Version

Coronavirus (COVID-19)

• Dexamethasone in COVID-19 treatment: Analyzing monotherapy and combination therapy approaches
• Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial
• Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19
• Long-term functional prognosis with tocilizumab in severe COVID-19 infection: A study on mechanically ventilated ICU patients
• Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review
• US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients
• Effectiveness of molnupiravir as early treatment for COVID-19 to prevent mortality and hospitalisation in high-risk adults
• Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY)
• Ritonavir-Boosted Nirmatrelvir Prescribing Information
• The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
• Vaccines and therapeutics for immunocompromised patients with COVID-19
• Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
• The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era
• Long COVID: major findings, mechanisms and recommendations
• CDC: COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised
• IDSA and CDC COVID-19 Real-Time Learning Network: Immunocompromised Populations
• COVID-19 Drug Interactions
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19
• Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation
• NIH COVID-19 Treatment Guidelines
• FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products
• Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2)
• Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER)
• Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
• CDC Coronavirus Disease 2019 (COVID-19) Resources
• WHO Resources: COVID-19 Pandemic
• JAMA Patient Page: Oral antiviral medications for COVID-19
• Molnupiravir EUA
• Nirmatrelvir EUA

Cytomegalovirus (CMV)

• Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
• About CMV For Patients
• Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients
• Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation
• Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
• Letermovir for Secondary Prophylaxis of CMV Infection
• Cytomegalovirus (CMV) Infection
• Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients

Gram-Negative Bacterial Infections

• Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies
• Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: New data from CREDIBLE-CR
• Gram-negative Bacteria Infections in Healthcare Settings
• IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0
• Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Herpes Zoster

• What You Can Expect After Getting Shingrix Vaccine Fact Sheet

HIV

• HIV Compendium of Best Practices
• Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
• INSTI Drug Interactions
• HIV and Drug-resistance Testing
• Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
• Adherence to the Continuum of Care
• Drug-Drug Interactions
• Drug Database: Cabotegravir
• Women with HIV
• Adverse Effects of Antiretroviral Therapy
• Considerations for Antiretroviral Therapy in the Older Patient
• Stanford University HIV Drug Resistance Database
• Understanding HIV Laboratory Tests – for Patients
• NNRTI Drug Interactions
• NRTI Drug Interactions
• PI Drug Interactions
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables
• What to Start: Selecting a First HIV Regimen

PrEP

• Drug Information on Lenacapavir
• Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
• Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
• CDC: PrEP Guidelines – 2021 Update
• Patient/Clinician Handout: PrEP 2-1-1
• HIV PrEP With FTC/TDF Among Cisgender Women
• Equity of Prep Uptake by Race, Ethnicity, Sex, and Region in the US in the First Decade of Prep
• Characteristics Associated with PrEP Discussion and Use Among Transgender Women Without HIV Infection – National HIV Behavioral Surveillance
• Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
• Safety Review of TDF/FTC PrEP for Pregnant Women at Risk of HIV Infection
• PrEP Resources in all 50 States
• National Clinician Consultation Center for PrEP
• Preexposure Prophylaxis for the Prevention of HIV Infection of the United States – 2021 Update
• Quick Guide: 2021 PrEP Update
• HIV Prevention Materials for Your Practice
• Let’s Stop HIV Together: HIV Prevention
• Drug information on cabotegravir
• Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083)
• Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084

Influenza

• Comparative Effectiveness of Cell-Based Versus Egg-Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022–2023 Season Among Adults 18–64 Years
• Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza
• FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
• What You Should Know About Influenza (Flu) Antiviral Drugs
• Similarities and Differences between Flu and COVID-19
• A Phase 3 Safety and Efficacy Study of Baloxavir Marboxil in Children Less Than 1 Year Old With Suspected or Confirmed Influenza
• Population Pharmacokinetic and Exposure-Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post-Exposure Prophylaxis in Children
• Influenza Antiviral Drug Resistance
• Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
• Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
• Seasonal Influenza Vaccine Effectiveness Studies
• Influenza Antiviral Medications: Summary for Clinicians
• Information for Clinicians on Influenza Virus Testing
• People at High Risk For Flu Complications
• Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children
• Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial

Invasive Fungal Infections

• CDC Fungal Diseases – Patient Information
• Information for Healthcare Professionals about Invasive Candidiasis
• Information for Healthcare Professionals about Mucormycosis
• Information for Healthcare Professionals about Aspergillosis

Molecular Diagnostics

• European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments
• The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document
• Clinical and cost implications of Biofire FilmArray® meningitis / encephalitis panel testing
• Performance of the BIOFIRE® Filmarray Pneumonia Plus Panel for quantifiable bacterial targets compared to semiquantitative culture methods

Pediatrics

• Recommendations for Prevention and Control of Influenza in Children, 2025–2026
• HPV Vaccination

Pneumococcal Disease

• Pneumococcal Disease
• Advisory Committee on Immunization Practices (ACIP): Pneumococcal Vaccine Recommendations
• Updated ACIP Recommendations and Evidence Review: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children
• Immunize.org Ask the Experts: Pneumococcal Vaccines for Children and Adults
• Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016
• PneumoRecs VaxAdvisor Mobile App
• Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines
• PCV15 Prescribing Information
• PCV20 Prescribing Information

Respiratory Syncytial Virus (RSV)

• Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study
• Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults
• Burden of Respiratory Syncytial Virus–Associated Hospitalizations in US Adults, October 2016 to September 2023
• RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults
• CYPRESS Phase 2b Data on the Efficacy and Immunogenicity of an Ad26.RSV.preF-based RSV Vaccine
• Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020
• Respiratory Syncytial Virus (RSV)
• CDC Factsheet. RSV in Older Adults and Adults with Chronic Medical Conditions
• Respiratory Syncytial Virus Infection

• Provider Resource: Interprofessional Collaborative Practice
  
• Provider Resource: Six-A Model of Counseling

Chronic Kidney Disease (CKD)

• Anemia in Chronic Kidney Disease

Lupus Nephritis

• Obinutuzumab prescribing information
• The Lupus Initiative: Eliminating Health Disparities in Lupus
• KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis
• 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
• Lupus Foundation of America: Lupus Nephritis Information Center
• National Kidney Foundation: Lupus Nephritis
• Lupus Health Disparities in the United States: A Framework of Barriers and Facilitators for Reducing Disease Burden in Racial and Ethnic Minorities
• New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis
• Novel Therapeutics for Management of Lupus Nephritis: What Is Next?
• Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
• Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
• Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

Alzheimer’s Disease

• Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
• Alzheimer’s Disease Facts and Figures 2024
• Focusing on earlier diagnosis of Alzheimer’s disease
• For Patients: Treatments for Alzheimer’s
• Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
• Alzheimer’s disease drug development pipeline
• Alzforum: news and information dedicated to Alzheimer’s disease

Amyotrophic Lateral Sclerosis

• NIH Amyotrophic Lateral Sclerosis Fact Sheet

Migraine

• The American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice
• Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians
• Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders (ICHD), 3rd edition
• Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine
• Setting higher standards for migraine prevention: A position statement of the International Headache Society
• CGRP Therapies are a First-Line Option for the Prevention of Migraine: An American Headache Society Position Statement Update
• Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
• Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Phase 3 Trial
• Atogepant for the Prevention of Episodic Migraine in Adults: A Phase 2b/3 Trial
• Time Course of Efficacy of Atogepant for the Preventive Treatment of Migraine: The ADVANCE Trial
• Long-term Safety, Efficacy and Functional Outcomes of Atogepant for the Preventive Treatment of Migraine
• Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Adults for Whom Conventional Oral Preventive Treatments Have Failed (ELEVATE): A Phase 3b Trial
• Efficacy, Safety, and Tolerability of Rimegepant Orally Disintegrating Tablet for the Acute Treatment of Migraine: A Phase 3 Trial
• Oral Rimegepant for Preventive Treatment of Migraine: A phase 2/3 Trial
• Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine in Japan
• Effects of Rimegepant 75 mg on Monthly Migraine Days: A 52-Week, Open-Label Extension Study
• A 52-week Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Rimegepant for the Preventive Treatment of Migraine
• Monthly Migraine Days, Tablet Utilization, and Quality of Life Associated with Rimegepant: Post Hoc Results from an Open Label Safety Study
• Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment
• Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
• Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
• Real-world Effectiveness, Satisfaction, and Optimization of Ubrogepant for the Acute Treatment of Migraine in Combination with OnabotulinumtoxinA: The COURAGE Study
• Reduction of Pain and Functional Disability Over Time in Patients Treated with Zavegepant: A Post-Hoc Analysis
• Safety, Tolerability, and Efficacy of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine: A Phase 3 Trial
• Efficacy and Safety of Intranasal Agents for the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis
• Diagnosis and Management of Migraine in Ten Steps
• Pathophysiology of Migraine: A Disorder of Sensory Processing
• Migraine Burden of Disease: From the Patient’s Experience to a Socio-Economic View
• Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4 Trial
• Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Trial
• CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review
• Prevalence and Burden of Migraine in the United States: A Systematic Review
• Red and Orange Flags for Secondary Headaches in Clinical Practice: SNNOOP10 List
• Frequently Asked Questions About Migraine Symptoms
• Atogepant for the Preventive Treatment of Migraine

Multiple Sclerosis (MS)

• Clinician Pocket Guide: What to Screen For and What to Follow When Using Disease-Modifying Therapies (DMTs)
• Adherence — Patient Information
• Resources for You and Your Practice
• Mobile Applications for People with Multiple Sclerosis (MS)
• Family Planning and Pregnancy With Multiple Sclerosis
• Disease-modifying Therapies for MS

Myasthenia Gravis

• Myasthenia Gravis Foundation of America
• NIH – Myasthenia Gravis
• Treatment options for myasthenia gravis
• New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making
• Myasthenia gravis: the future is here
• Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
• The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis

Stroke

• Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines
• Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
• Signs and Symptoms of a Stroke
• Recognize Warning Signs of a Stroke (Act FAST)
• American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention

• AACE Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update
• ADA Standards of Care in Overweight and Obesity
• Current and Future Medications for Obesity Treatment
• The Lancet Commission: Definition and Diagnostic Criteria of Clinical Obesity
  
• Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impacts
  
• Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
• ADA: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes
• Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
• Amylin Adventure – Vindico Medical Education
• YouTube – Amylin Adventure: Biology and Modes of Action
• Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
• Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
• What is the pipeline for future medications for obesity?
• Central nervous system pathways targeted by amylin in the regulation of food intake
• SURMOUNT-1: 3-Year Safety on Tirzepatide for Obesity Treatment and Diabetes Prevention
• SURMOUNT-1 Substudy: Body Composition Changes During Weight Reduction With Tirzepatide in Adults With Obesity or Overweight
• First-in-class GLP-1 and Amylin Receptor Agonist, Amycretin: Phase 1 Trial
• Subcutaneous Amycretin: A Phase 1b/2a Randomised Controlled Study
• REDEFINE-1 Phase 3a: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
• REDEFINE-2 Phase 3a: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
• Evolving Approaches for Pharmacological Therapy of Obesity
• New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial
• SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
• SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
• Obesity and CVD: A Scientific Statement from the American Heart Association
• Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
• AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
• Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
• Patient Resource: Your Obesity Care Team
• Internet Tracking Tools for the Bariatric Patient
• CDC: Healthy Weight, Nutrition, and Physical Activity—Planning Meals
• Who’s Who on the Obesity Care Team – Patient Education
• Curated Resources for the Management of Obesity in the Primary Care Setting
• Guide for the Management of Obesity in the Primary Care Setting
• Prescription Medications to Treat Overweight and Obesity
• Bariatric Surgery: Patient Materials
• STOP Obesity Alliance – WHY WEIGHT? A Guide to Discussing Obesity & Health with Your Patients
• American Board of Obesity Medicine (ABOM)
• How To Use Fruits and Vegetables – Patient Handout
• Rethink Your Drink – Patient Materials
• Childhood Obesity Facts

Age-Related Macular Degeneration (AMD)

• Age-Related Macular Degeneration Preferred Practice Patterns 2024
• Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial
• The Age-Related Eye Disease 2 Study: Micronutrients in the Treatment of Macular Degeneration
• Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration
• Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab
• Interim Results of the Phase III Portal Extension Trial of the PDS with Ranibizumab in nAMD
• FARETINA-AMD: Early Outcomes After Initiation of Faricimab for nAMD
• The Promise of TKIs in nAMD and DR
• Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes
• Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond
• Age-Related Macular Degeneration (AMD) for Patients
• Impact of Anti-VEGF on Vision Outcomes in nAMD: 6-Year Analysis of the AAO IRIS® Registry
• TENAYA/LUCERNE: Two-Year Results from the Phase 3 nAMD Trials of Faricimab with T&E Dosing
• Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
• What AREDS means for you?
• Mayo Clinic: Dry Macular Degeneration
• Understanding Your AMD – Patient Handout
• Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration – Patient Handout
• Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education

Cataract and/or Refractive Surgery

• AAO Refractive Surgery Preferred Practice Patterns 2024
• Saving of Time Using a Software-Based versus a Manual Workflow for Toric Intraocular Lens Calculation and Implantation
• AAO Cataract in the Adult Eye Preferred Practice Pattern 2021
• Cataract and Refractive Lens Exchange Questionnaire
• Post-Refractive IOL Calculator
• American Society of Cataract and Refractive Surgery
• Toric IOL Calculator
• Preparing for Cataract Surgery – Postoperative Concerns – Patient Handout

Conjunctivitis

• Conjunctivitis: What is Pink Eye? – Patient Information
• Help Protect Yourself From Getting & Spreading Pink Eye (Conjunctivitis) – Patient Handout

Demodex Blepharitis

• Multidisciplinary perspectives in Demodex blepharitis: A new view of treatment from clinical, payer, and patient perspectives
• Prevalence of Demodex Blepharitis in US Eye Care Clinic Patients as Determined by Collarettes: A Pathognomonic Sign
• Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis

Diabetic Macular Edema (DME)

• Eye Care of the Patient with Diabetes Mellitus
• Faricimab Treat-and-Extend for Diabetic Macular Edema. Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
• Intravitreal Aflibercept 8 mg for Diabetic Macular Edema. Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial
• Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial
• Impact of the Dexamethasone Implant on Slowing DR Progression: Post Hoc Analysis of the MEAD Study
• Diabetic Retinopathy Preferred Practice Pattern
• Long-term Treatment Patterns for DME: 6-Year Follow-Up in the IRIS® Registry
• PHOTON: Intravitreal Aflibercept 8 mg in DME: 48-Week Results, Phase 2/3 Trial
• Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema – Patient Handout
• Facts About Macular Edema
• 5 Year Outcomes After Aflibercept, Bevacizumab, or Ranibizumab for DME: Protocol T Extension Study

Diabetic Retinopathy

• Diabetic Retinopathy Preferred Practice Pattern
• Intravitreal Aflibercept for the Treatment of Diabetic Retinopathy Among Patients Who Completed PANORAMA: 1-Year Outcomes from the VOYAGE Extension Study
• Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial
• Understanding Diabetic Retinopathy – Patient Handout
• Diabetic Retinopathy Clinical Research Network Publications
• Diabetic Retinopathy: Causes, Symptoms, Treatment
• Protocol W: Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
• Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy

Geographic Atrophy

• Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
• Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial
• Unlocking geographic atrophy
• Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration
• Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
• Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel
• Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3

General

• FDA Prescribing Information for Professionals
• ICD-10-CM for Ophthalmology
• EyeNet Magazine
• National Institutes of Health Guidelines on Human Subjects Research
• AAO Preferred Practice Patterns
• Vicchrilli S. Savvy coder: telemedicine during the public health emergency.
• AAO.org: Home Eye Test for Adults

Glaucoma

• Primary Open-Angle Glaucoma Preferred Practice Patterns 2025
• Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
• Ocular effects of Rho kinase (ROCK) inhibition: a systematic review
• Netarsudil 0.02% Alters Episcleral Venous Flowrates: A Clinical Trial Using Erythrocyte-Mediated Angiography
• Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review
• Preservatives and ocular surface disease: A review
• The Glaucoma Foundation: Preservative-Free Glaucoma Eye Drops
• Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
• National Eye Institute: Glaucoma
• Bimatoprost Implant. Prescribing Information
• Microinvasive Glaucoma Surgery (MIGS)
• Xen Gel Stent: Directions for Use
• American Glaucoma Society

Inherited Retinal Diseases

• Genetic testing and diagnosis of inherited retinal diseases
• AAO Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations – 2022
• Patient Information – Inherited Retinal Diseases
• Foundation Fighting Blindness

Macular Disorders

• Understanding Vitreomacular Traction Syndrome – Patient Handout

Macular Telangiectasia

• What Is Macular Telangiectasia?
• Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2
• Revakinagene taroretcel-lwey. Package Insert
• Macular Telangiectasia Type 2: A Comprehensive Review

Neurotrophic Keratitis

• Nerve Growth Factor Treatment for Neurotrophic Keratopathy in the IRIS® Registry
• Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System
• Neurotrophic Keratitis: Pharmacological Treatments
• Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
• Cenegermin Prescribing Information
• Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
• Neurotrophic keratopathy: An updated understanding
• Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy

Neuromyelitis Optica Spectrum Disorder (NMOSD)

• Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
• International Delphi Consensus on the Management of AQP4-IgG+ NMOSD. Recommendations for Eculizumab, Inebilizumab, and Satralizumab
• Contemporary management challenges in seropositive NMOSD
• Guthy Jackson Foundation
• Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
• Neuromyelitis Optica Spectrum Disorder
• The Sumaira Foundation for NMO

Ocular Surface and Lid Margin Disease

• Improved Dry Eye Drugs for 2025 and Beyond
• TFOS DEWS III Diagnostic Methodology
• A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)
• Managing dry eye in 2025: Think bigger picture, multisystem – Optometry Times
• NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction
• TFOS Lifestyle: Impact of nutrition on the ocular surface
• Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists
• Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study
• Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
• AAO EyeWiki: Meibomian Gland Dysfunction (MGD)
• Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
• Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial
• A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
• Dry Eye: Patient Information
• American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome
• American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis
• Sjögren’s Syndrome Foundation

Plasminogen Deficiency

• Plasminogen Deficiency Foundation
• NORD: Congenital Type 1 Plasminogen Deficiency
• Rare Coagulation Disorders: Plasminogen Deficiency
• Interactions of the Fibrinolytic And Innate Immune Systems
• Treatment of Ligneous Conjunctivitis with Plasminogen Eyedrops
• Plasminogen, human-tvmh for the treatment of children and adults with plasminogen deficiency type 1
• Treating Type 1 Plasminogen Deficiency
• Case Report: Treating Respiratory Lesions with Plasminogen, human-tvmh

Presbyopia

• Presbyopia Treatment
• Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
• What Is Presbyopia? (Patient Material)
• A Review of Pharmacological Presbyopia Treatment
• Treatments for presbyopia coming soon

Retinal Vascular Diseases (RVO)

• Infographic: study design of the QUASAR randomised trial of aflibercept 8 mg in retinal vein occlusion
• Retinal Vein Occlusions PPP 2024
• BALATON and COMINO 72-Week Results: Faricimab T&E Dosing for Retinal Vein Occlusion
• Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion
• Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study
• Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
• Branch Retinal Vein Occlusion Information for Patients
• Central Retinal Vein Occlusion Information for Patients
• Understanding Your Retinal Vein Occlusion (RVO) – Patient Handout

Thyroid Eye Disease (TED)

• A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease
• Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells
• MON-360 Lonigutamab (Anti-IGF-1R Monoclonal Antibody) Reduces IGF-1-Mediated Hyaluronan Production in Thyroid Eye Disease Orbital Fibroblasts
• Efficacy and Safety of Veligrotug (VRDN-001), a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease (TED): THRIVE Phase 3 Topline Results
• Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
• Thyroid Eye Disease: Navigating Diagnosis and Treatment
• Patient Brochures
• Patient Material: Examining the Optics of TED

Uveitis

• A Guide to Ocular Inflammatory Disease. For Patients
• Uveitis. For Patients
• Treatment of Uveitis
• Anterior uveitis for the comprehensive ophthalmologist
• Development of Classification Criteria for the Uveitides: SUN
• Preparing for Your Appointment – Patient Handout

Vitreoretinal Surgery

• Preparing for a Vitrectomy – Patient Handout

Pain Management

• CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022

Anesthesia

• Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age
• Sugammadex for our little ones: a brief narrative review
• Statement on Practice Recommendations for Pediatric Anesthesia
• Sugammadex and recurarization in an infant
  
• Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study
• Smart Tots

Gastroenterology

• Facts About Crypto and Swimming Pools – Patient Handout
• Cryptosporidiosis
• Giardiasis
• For Parents: Treating Pediatric Dehydration
• Swimming Pool Hygiene
• Children’s Health
• GI Kids

Invasive Meningococcal Disease (IMD)

• Long-Term Impacts of Invasive Meningococcal Disease on Survivors and Their Caregivers in the United States and Canada
• AAP: Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, 2026
• US HHS: Childhood Immunization Schedule by Recommendation Group, 2025
• Vaccine for Children Program
• The epidemiology of bacterial meningitis in the United States during 2008–2023: an analysis of active, laboratory, population-based, multistate surveillance data
• ACIP: Meningococcal Vaccination Recommendations, 2020
• Meningococcal Vaccination of Adolescents in the United States: Past Successes and Future Considerations
• Managing Meningococcal Disease Risk in Patients Receiving Complement Inhibitor Therapy
• Yellow Book: Meningococcal Disease
• Addressing Parental Vaccine Hesitancy towards Childhood Vaccines in the United States: A Systematic Literature Review of Communication Interventions and Strategies
• WHO: Communicating about vaccination with caregivers and patients: a communication training module for health workers
• Utilization of Provider-Patient Communication Tools and Approaches to Facilitate Vaccine Confidence: A Systematic Review
• Preventing Meningococcal Disease in US Adolescents and Young Adults Through Vaccination

Psychiatry

• CDC what is ADHD?
• Symptoms of ADHD
• Diagnosing ADHD

Respiratory Syncytial Virus (RSV)

• Protecting Your Baby from RSV: Patient Resource
• Early-life respiratory syncytial virus disease and long-term respiratory health
• The disease burden of respiratory syncytial virus in Infants
• AAP: RSV Prevention Recommendations
• HARMONIE: 180-day efficacy of nirsevimab against hospitalisation for RSV LRTI in infants
• HARMONIE Phase 3b: Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
• MELODY Phase 3: Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
• MATISSE Phase 3: Efficacy, Safety, and Immunogenicity of the Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
• Preterm Birth Frequency and Associated Outcomes From the MATISSE Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
• CLEVER: Clesrovimab for Prevention of RSV Disease in Healthy Infants
• CDC: Infant RSV Prevention Options
• Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children
• First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants
• Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting
• RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
• The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
• Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months – United States, April 2024
• Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study
• Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment
• CDC: FAQs About RSV Immunization with mAb for Children ≤ 19 Months
• AAP Nirsevimab Administration Visual Guide
• ACOG RSV Prevention Practice Advisory
• For Healthcare Providers: RSV Prevention Information
• MMWR: ACIP Recommendations for Nirsevimab
• MMWR: ACIP Recommendations for Maternal RSV Vaccine
• Nirsevimab Prescribing Information
• Maternal RSV Vaccine Prescribing Information
• Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE)
• Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak
• CDC Recommendations for RSV Prevention
• Patient Brochure: RSV in Infants and Young Children

Vaccine-Preventable Diseases: General

• Communication interventions to reduce parental vaccine hesitancy: A systematic review
• Navigating vaccine hesitancy: Strategies and dynamics in healthcare professional-parent communication
• Pediatric Vaccination – Information for Parents

Vaccine-Preventable Diseases: Influenza

• Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
• CDC: 2025–2026 Flu Season
• Influenza Activity in the United States during the 2024–2025 Season and Composition of the 2025–2026 Influenza Vaccine
• ACIP Recommendations for Prevention and Control of Influenza in Children, 2025-2026
• Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023–2024 Season
• Relative Vaccine Effectiveness of Cell- vs Egg-Based Quadrivalent Influenza Vaccine Against Test-Confirmed Influenza Over 3 Seasons Between 2017 and 2020 in the United States
• Flu: A Guide for Parents
• Make a Strong Influenza Vaccine Recommendation
• Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
• Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States

Vaccine-Preventable Diseases: Human Papillomavirus (HPV)

• Top 10 Tips for HPV Vaccination Success
• CDC: ACIP’s HPV Vaccination Recommendations
• CDC: Talking to Parents about HPV Vaccine
• Pediatric Vaccination – Information for Parents
• CDC Resources, Education & References for HPV Vaccination
• Human Papillomavirus Vaccination: ACOG Committee Opinion Vaccination
• HPV Vaccination: What Everyone Should Know
• CDC HPV Vaccine Recommendations
• Standing Order for HPV Vaccine
• Centers for Disease Control and Prevention HPV Vaccine Recommendations
• Recommended Immunization Schedule for Persons Aged 0 Through 18 Years – 2025
• Why Are Childhood Vaccines So Important? – Educational Tool for Parents

Binge Eating Disorder (BED)

• Definition & Facts for Binge Eating Disorder – NIH Patient Education

Bipolar Disorder

• Bipolar Disorder Diagnosis and Treatment for Patients

Depression

• National Alliance on Mental Health (NAMI) – Depression
• NIH Information and Resources on Depression (Including Perinatal Depression)
• U.S Preventive Services Task Force: Perinatal Depression – Preventive Interventions
• CDC Patient Information and Resources: Depression During and After Pregnancy
• Feeling sad after your baby is born? Video from the American Academy of Pediatrics
• Perinatal depression: A review
• BPRS Brief Psychiatric Rating Scale
• Montgomery-Asberg Depression Rating Scale
• Edinburgh Postnatal Depression Scale
• Depression – stopping your medicine – Patient Handout
• Major Depressive Disorder – Patient Handout
• What are the Causes of Depression? – Patient Handout

Schizophrenia

• Schizophrenia educational resources
• Support Groups and Supportive Resources – Patient Handout
• Approach to Schizophrenia Management At-A-Glance – Patient Handout
• Schizophrenia: Recognizing the Symptoms and Getting Treatment – Patient Handout

Substance Use Disorders

• Providers’ Clinical Support System for Opioid Therapies (PCSS-O): Educational Resources
• Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Tardive Dyskinesia (TD)

• Abnormal Involuntary Movement Scale exam

Interstitial Lung Disease (ILD)

• Bridging Specialties: ILD Clinician Toolkit
• Pulmonary Fibrosis Foundation Educational Resources
• Nintedanib Prescribing Information
• Pirfenidone Prescribing Information
• Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
• Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Non-Tuberculous Mycobacteria

• Learn about NTM Lung Disease
• “INSIGHT” A Patient’s Perspective on NTM
• CDC Clinician Resources on NTM Infection
• NORD Nontuberculous Mycobacterial Lung Disease Patient and Family Resources

Pulmonary Hypertension

• Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcome
• Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
• Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
• Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative-Group 3 pulmonary hypertension
• Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study
• Pulmonary Fibrosis Foundation: PH-ILD for Patients
• Pulmonary Fibrosis Foundation: PH-ILD for Healthcare providers
• Pulmonary Hypertension Association: Patient Resources
• PAH Risk Score Calculators
• Clinical application of risk assessment in PAH: Expert center APRN recommendations
• American Lung Association PAH Patient Resources
• Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Biosimilars

• Biosimilars: More Treatment Options Are on the Way
• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US

Gout

• Alliance for Gout Awareness Resources
• Gout Patient Education & Resources
• PROTECT: Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label clinical trial
• RECIPE: Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
• MIRROR RCT: A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
• Impact of Uncontrolled Gout on Quality of Life and Importance of Open Dialogue With Patients
• Pegloticase Prescribing Information
• Gout Patient fact Sheet

IgG4-Related Disease (IgG4-RD)

• 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease
• (ACR) Information on IgG4-Related Disease: What they are, Getting Diagnosed, Treatment Options, and More
• MITIGATE – Phase 3 Clinical Trial: Efficacy and Safety of Inebilizumab in IgG4-Related Disease

Psoriatic Arthritis

• Psoriatic Arthritis – Disease Primer

Spondyloarthritis

• ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
• JAK1 selective inhibitors for the treatment of spondyloarthropathies
• Recognizing Axial Spondyloarthritis: A Guide for Primary Care
• Spondylitis Association of America: Resources and Support
• Spondyloarthritis Patient Fact Sheet
• What Is Axial Spondyloarthritis (AxSpA)?

Juvenile Idiopathic Arthritis (JIA)

• ACR Update of Recommendations to the Treatment of JIA
• What is JIA? – Patient Handout

Lupus

• Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
• Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
• Lupus Foundation of America Caregiver Toolkit
• ACR Patient Fact Sheet: Lupus
• Belimumab prescribing information
• Voclosporin prescribing information

Rheumatoid Arthritis (RA)

• RA and Vaccinations
• The Purple Book for Biosimilars
• RA Overview (for Patients)
• RA Treatment (for Patients)
• FDA Information on Biosimilars (for Patients)

Systemic Sclerosis

• Understanding Scleroderma: National Scleroderma Foundation Patient Education

Vasculitis

ANCA-Associated Vasculitis

• EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
• ANCA-Associated Vasculitis
• EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

• Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
• Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis
• NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis
• National Organization for Rare Disorders: Churg Strauss Syndrome

Giant Cell Arteritis

• Giant Cell Arteritis – Fast Facts for Patients
• Giant Cell Arteritis – Vasculitis Foundation
• ACR/EULAR Classification of Giant Cell Arteritis

Menopause

• Women’s experiences and expectations during the menopause transition: a systematic qualitative narrative review
• Exploring the Lived Experiences of Black Women During the Menopausal Transition
• African American women’s experiences of menopause: A focus group study
• Patient Resource – Beyond Hot Flashes: Empowering Women Through Menopause
• Menopause Society for Clinicians
• Menopause Society for Women
• Patient Resource: Deciding About Hormone Therapy Use
• Patient Resource: Vaginal Dryness
• Patient Resource: Nonhormone Treatments for Hot Flashes and Night Sweats
• “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society”
• Disparities in Reproductive Aging and Midlife Health between Black and White women: The Study of Women’s Health Across the Nation (SWAN)